Related Experiment Videos
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines
1Department of Medicine, University of Pittsburgh, Pennsylvania, USA.
Abstract:
Non-small cell lung cancer (NSCLC) is fatal in approximately 90% of all cases due to the failure of systemic therapy, secondary to resistance to chemotherapy. In such malignancies new therapeutic paradigms are needed. One such approach takes advantage of normal physiologic growth regulatory mechanisms, such as terminal cellular differentiation or apoptosis. Suramin, as an antineoplastic drug, has shown efficacy in the treatment of prostate cancer and is capable of promoting differentiation in several human cancer cell lines. Little is known about the differentiating effects of suramin in lung cancer. In the present investigation we evaluated the ability of suramin to induce cross-linked envelope (CLE) formation, as a common marker for squamous differentiation and apoptosis, in three representative human non-small cell lung cancer cell lines: NCI-H226 (squamous), NCI-H358 (bronchoalveolar [adenocarcinoma]), and NCI-H596 (adenosquamous). Among agents that we have tested, suramin demonstrated the unique ability to induce spontaneous CLE formation in the two cell lines with squamous features, NCI-H226 and NCI-H596. Suramin induced CLE formation was accompanied by DNA fragmentation, a marker for apoptosis, in NCI-H596 and NCI-H358, but not in NCI-H226. Stimulation of CLE formation by suramin correlated with the rapid induction of both type II transglutaminase (TG) activity and involucrin expression. These parameters were protein synthesis independent, suggesting posttranslational mechanisms of suramin activity. Induction of differentiation/apoptosis markers by suramin did not correlate with its effect on growth. Modulation of signal transduction is a likely candidate mechanism for suramin activity in lung cancer. The relationship between growth, squamous differentiation, and apoptosis is considered.
Insights
Suramin promotes squamous differentiation and apoptosis in non-small cell lung cancer (NSCLC) cell lines. This antineoplastic drug induces cross-linked envelope formation and DNA fragmentation, suggesting novel therapeutic potential for NSCLC.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- Non-small cell lung cancer (NSCLC) has a poor prognosis due to therapeutic resistance.
- Novel therapeutic strategies targeting cancer cell differentiation and apoptosis are needed.
- Suramin shows promise as an antineoplastic agent, particularly in prostate cancer.
Purpose of the Study:
- To evaluate suramin's ability to induce squamous differentiation and apoptosis in NSCLC cell lines.
- To investigate the markers of differentiation and apoptosis induced by suramin.
- To explore the underlying mechanisms of suramin's action in lung cancer.
Main Methods:
- Tested suramin's effect on three human NSCLC cell lines (NCI-H226, NCI-H358, NCI-H596).
- Assessed cross-linked envelope (CLE) formation as a marker for squamous differentiation.
- Measured DNA fragmentation, type II transglutaminase (TG) activity, and involucrin expression.
Main Results:
- Suramin induced CLE formation in squamous NSCLC cell lines (NCI-H226, NCI-H596).
- Suramin treatment led to DNA fragmentation in NCI-H596 and NCI-H358 cells.
- CLE formation correlated with increased TG activity and involucrin expression, independent of protein synthesis.
Conclusions:
- Suramin effectively induces markers of squamous differentiation and apoptosis in specific NSCLC subtypes.
- The observed effects appear to be mediated by post-translational mechanisms.
- Suramin's impact on differentiation and apoptosis may offer a new therapeutic avenue for NSCLC, potentially through signal transduction modulation.